Amalgamated Bank Lowers Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Amalgamated Bank lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,497 shares of the company’s stock after selling 305 shares during the period. Amalgamated Bank’s holdings in Omnicell were worth $588,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Arizona State Retirement System increased its position in Omnicell by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after purchasing an additional 357 shares during the period. Texas Permanent School Fund Corp increased its holdings in Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock valued at $1,158,000 after buying an additional 479 shares during the period. Diversified Trust Co increased its holdings in Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after buying an additional 494 shares during the period. GAMMA Investing LLC raised its stake in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in Omnicell by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after buying an additional 600 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Down 2.0 %

Shares of Omnicell stock opened at $45.67 on Friday. The company has a 50 day moving average price of $44.19 and a 200 day moving average price of $36.70. The firm has a market capitalization of $2.12 billion, a P/E ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74.

Wall Street Analyst Weigh In

Several research firms have recently commented on OMCL. Benchmark reissued a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $50.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.